PTI 428

Drug Profile

PTI 428

Alternative Names: PTI-428

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase I/II Cystic fibrosis

Most Recent Events

  • 28 Jul 2017 Phase-I clinical trials in Cystic fibrosis (Adjunctive treatment) in United Kingdom (PO) (NCT03258424)
  • 29 Jun 2017 Preliminary safety, efficacy and pharmacokinetic data from a phase I study in Cystic fibrosis released by Proteostasis Therapeutics
  • 21 Jun 2017 Proteostasis Therapeutics plans a Proof-of-concept trial for the triple combination proof of concept combining PTI 428, PTI 801 and PTI 808
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top